Compare VEON & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VEON | CRNX |
|---|---|---|
| Founded | 1992 | 2008 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.9B |
| IPO Year | 2010 | 2018 |
| Metric | VEON | CRNX |
|---|---|---|
| Price | $49.78 | $35.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | $73.25 | ★ $74.78 |
| AVG Volume (30 Days) | 130.4K | ★ 885.6K |
| Earning Date | 03-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,039,000.00 |
| Revenue This Year | $10.59 | $730.30 |
| Revenue Next Year | $7.07 | $179.48 |
| P/E Ratio | $6.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.55 | $24.10 |
| 52 Week High | $64.00 | $57.99 |
| Indicator | VEON | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 27.27 |
| Support Level | $44.09 | $33.23 |
| Resistance Level | $55.96 | $37.23 |
| Average True Range (ATR) | 3.79 | 1.63 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 34.78 | 6.44 |
VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.